Palavras-chave
Assistência pré-hospitalar
Trauma
Choque hemorrágico
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Analisar as evidências científicas sobre a segurança e eficácia na administração do ácido tranexâmico (TXA) no ambiente pré-hospitalar e o impacto de sua utilização na mortalidade das vítimas. Métodos: Trata-se de uma revisão integrativa de literatura utilizando a base de dados PubMed Central (PMC), realizada entre Agosto e Dezembro de 2023. Foram considerados artigos publicados entre 2013 e 2022 nos idiomas espanhol, francês, inglês e português. Resultados: Ao todo, 5.561 artigos foram encontrados, sendo selecionados 18 para compor a amostra final. Apesar de restritos a pacientes selecionados, a maioria dos artigos evidenciam uma redução na mortalidade e no tempo de permanência hospitalar das vítimas de trauma grave com risco de sangramento e traumatismo cranioencefálico moderado, uma menor taxa de transfusão de hemoderivados durante a internação, mesmo benefício não observado nas vítimas de trauma craniano graves com pontuação na escala de coma de Glasgow menor que 8. Considerações finais: O uso do TXA se mostrou efetivo na redução da mortalidade dos pacientes politraumatizados graves com risco de sangramento. O seu uso ainda está restrito a indivíduos com idade superior a 12 anos, tendo seu uso indicado em até 3 horas do trauma, idealmente na primeira hora da injúria, evidenciam alguns estudos.
Referências
BOSSERS SM, et al. Association Between Prehospital Tranexamic Acid Administration and Outcomes of Severe Traumatic Brain Injury. JAMA Neurology 2020; 78(3): 338–345.
DEEB A-P, et al. Prehospital synergy: Tranexamic acid and blood transfusion in patients at risk for hemorrhage. J Trauma Acute Care Surg 2022; 93(1): 52–58.
DIXON AL, et al. TXA Administration in the Field Does Not Affect Admission TEG after Traumatic Brain Injury. J Trauma Acute Care Surg 2020; 89(5): 900–907.
GRUEN RL, et al. Prehospital Tranexamic Acid for Severe Trauma. N Engl J Med 2023; 389(2): 127–136.
GUYETTE FX, et al. Tranexamic Acid During Prehospital Transport in Patients at Risk for Hemorrhage After Injury: A Double-blind, Placebo-Controlled, Randomized Clinical Trial. JAMA Surgery 2020; 156(1): 11–20.
IMACH S, et al. The impact of prehospital tranexamic acid on mortality and transfusion requirements: match-pair analysis from the nationwide German TraumaRegister DGU®. Crit Care 2021; 25(1): 277.
KUNZE-SZIKSZAY N, et al. The pre-hospital administration of tranexamic acid to patients with multiple injuries and its effects on rotational thrombelastometry: a prospective observational study in pre-hospital emergency medicine. Scandinavian Journal of Trauma, Ressuscitation and Emergency Medicine 2016; 24(1): 122.
MITRA B, et al. Protocol for a multicentre prehospital randomised controlled trial investigating tranexamic acid in severe trauma: the PATCH-Trauma trial. BMJ Open 2021; 11(3): e046522.
NEGAHI A, et al. The effect of early tranexamic acid on bleeding, blood product consumption, mortality and length of hospital stay in trauma cases with hemorrhagic shock: a randomized clinical trial. J Prev Med Hyg 2021; 62 (4): E958–E965.
NEEKI MM, et al. Tranexamic Acid in Civilian Trauma Care in the California Prehospital Antifibrinolytic Therapy Study. Western Journal of Emergency Medicine 2018; 19(6): 977–986.
NUTBEAM T, et al. Use of tranexamic acid in major trauma: a sex-disaggregated analysis of the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2 and CRASH-3) trials and UK trauma registry (Trauma and Audit Research Network) data. British Journal of Anaesthesia 2022; 129: 191–199.
QUINTANA-DÍAZ M, et al. Advancing in the understanding of coagulopathy during hemorrhagic shock: From the triad to the deadly pentad 2022; 50(4): 1–8.
ROBERTS I, et al. Tranexamic acid in bleeding trauma patients: an exploration of benefits and harms. Trials 2017; 18(1): 48.
ROBERTS I, et al. Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT. Health Technology Assessment 2021; 25(26):1–76.
ROWELL SE, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA 2020; 324(10): 961–974.
STEIN P, et al. The Impact of Prehospital Tranexamic Acid on Blood Coagulation in Trauma Patients. Anesthesia and Analgesia 2018; 126(2): 522–529.
THE CRASH-3 TRIAL COLLABORATORS. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019; 394(10210): 1713–1723.
THE UK CRASH-4 TRIAL COLLABORATION. Intramuscular tranexamic acid for symptomatic mild traumatic brain injury in older adults: a pilot randomised, placebo-controlled trial (The CRASH-4 trial pilot phase). 2022.
WILLIAMS J, et al. A cost-effectiveness and value of information analysis to inform future research of tranexamic acid for older adults experiencing mild traumatic brain injury. Trials 2022; 23(1): 370.
YUSSOF SJM, et al. Administration of tranexamic acid for victims of severe trauma within pre-hospital care ambulance services (PHCAS) in Malaysia. Med J Malaysia 2019; 74(4): 300–306.